Sustainability | December 12, 2025
Granules India receives official 2025 CDP rating
The company had achieved the highest "A" rating in Climate Change
The company had achieved the highest "A" rating in Climate Change
The product will be marketed by Dr. Reddy's Laboratories Inc.
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The company will respond to the US FDA within the stipulated timelines
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Subscribe To Our Newsletter & Stay Updated
